Used for the treatment of mesothelioma! The English silicon intelligent pan-TEAD inhibitor ISM6331 has received FDA IND approval.

Clinical-stage biotechnology company EngTech Intelligence, driven by generative artificial intelligence (AI), announced that its internally developed potential "best-in-class" pan-TEAD inhibitor ISM6331 received Investigational New Drug (IND) approval from the US Food and Drug Administration (FDA) in July 2024 for the treatment of mesothelioma, following the orphan drug designation (ODD) received in June 2024. This brings the number of innovative molecules approved for clinical trials by EngTech Intelligence to 9. ISM6331 is a potent, non-covalent small molecule inhibitor with a novel molecular scaffold that targets the transcriptional enhancer associated domain (TEAD) protein family. As a key regulatory factor in the Hippo pathway, TEAD plays an important role in tumor progression, metastasis, cancer metabolism, immunity, and drug resistance. Sujata Rao, Chief Medical Officer of EngTech Intelligence, stated that the consecutive orphan drug designation and IND approval for the TEAD project are very encouraging for us. During the preclinical development stage, ISM6331 validated the AI-driven innovative research and development path and demonstrated the top-notch expertise of EngTech Intelligence's research team. We will expedite patient recruitment in the US and accelerate the application of ISM6331 in mesothelioma and other Hippo pathway-related tumors to meet the unmet clinical needs as soon as possible.